The effect of opioid-free anesthesia protocol on the early quality of recovery after major surgery (SOFA trial): study protocol for a prospective, monocentric, randomized, single-blinded trial

Maxime Léger1,2*, Solène Pessiot-Royer1, Tristan Perrault1, Elsa Parot-Schinkel3, Fabienne Costerousse1, Emmanuel Rineau1 and Sigismond Lasocki1

Abstract

Background: Since the 2000s, opioid-free anesthesia (OFA) protocols have been spreading worldwide in anesthesia daily practice. These protocols avoid using opioid drugs during anesthesia to prevent short- and long-term opioid side effects while ensuring adequate analgesic control and optimizing postoperative recovery. Proofs of the effect of OFA protocol on optimizing postoperative recovery are still scarce. The study aims to compare the effects of an OFA protocol versus standard anesthesia protocol on the early quality of postoperative recovery (QoR) from major surgeries.

Methods: The SOFA trial is a prospective, randomized, parallel, single-blind, monocentric study. Patients (n = 140) scheduled for major plastic, visceral, urologic, gynecologic, or ear, nose, and throat (ENT) surgeries will be allocated to one of the two groups. The study group (OFA group) will receive a combination of clonidine, magnesium sulfate, ketamine, and lidocaine. The control group will receive a standard anesthesia protocol based on opioid use. Both groups will receive others standard practices for general anesthesia and perioperative care. The primary outcome measure is the QoR-15 value assessed at 24 h after surgery. Postoperative data such as pain intensity, the incidence of postoperative complication, and opioid consumption will be recorded. We will also collect adverse events that may be related to the anesthetic protocol. Three months after surgery, the incidence of chronic pain and the quality of life will be evaluated by phone interview.

Discussion: This will be the first study powered to evaluate the effect of OFA versus a standard anesthesia protocol using opioids on global postoperative recovery after a wide range of major surgeries. The SOFA trial will also provide findings concerning the OFA impact on chronic pain incidence and long-term patient quality of life.
Background

Opioids play an essential part in pain control during anesthesia, even in the “balanced anesthesia” concept. However, opioids are associated with many side effects (e.g., nausea, vomiting, ileus, sedation, delirium, addiction, hyperalgesia) [1]. Since the 2000s, opioid-free anesthesia (OFA) protocols have been spreading worldwide in anesthesia daily practice. These protocols avoid using opioid drugs during anesthesia to prevent short- and long-term opioid side effects while ensuring adequate analgesic control and optimizing postoperative recovery.

The emergence of OFA protocols parallels the emergence of an “opioid crisis” (i.e., a dramatic increase in opioid addiction and of related death), particularly in the USA, with a significant proportion of treatment initiation during the perioperative period [2, 3]. This lead scientific societies to reduce patients’ exposure to opioids [4]. OFA is based on a multimodal combination of nonopioid agents such as N-methyl-d-aspartate antagonists, anti-inflammatory drugs, local anesthetics, and alpha-2 agonists. Currently, the anesthetic literature regarding OFA remains controversial, with studies confirming or not its benefit [5–8]. The most recent randomized controlled study published is negative but focused only on opioid-related adverse events [9].

Suggested effects reported in previous studies of multimodal use of OFA are intraoperative hemodynamic stability [10], analgesic efficacy [11, 12], and decreased opioid-associated adverse effects (especially on postoperative nausea and vomiting) [13–15]. The application of OFA protocols could also address other effects of opioid use, such as addiction, development of pain chronicity, or even immunomodulation that may negatively impact postoperative infection or cancer [16]. Combining all these benefits may improve the overall quality of postoperative recovery (QoR) [11]. In addition, no data are available on longer-term outcomes.

We aim to perform a study to determine the impact of an OFA protocol versus standard of care (i.e., opioid use during anesthesia) on the QoR after major surgeries.

Methods

In this superiority, randomized, controlled, single-blinded, single-center trial, we plan to include patients scheduled to undergo elective major surgery (plastic, visceral, urologic, gynecologic, or ENT surgeries). The patients will be allocated to receive either an OFA protocol or a standard anesthesia protocol (Fig. 1). The study will be conducted at the Angers University Hospital, Angers, France. This trial is designed following the Standard Protocol Items (SPIRIT guidelines). Figures 2 and 3 provide an overview of the study plan.

The French Institutional Review Board “Eastern III” (Nancy, France, number: 2021-A00364-37) and the National Agency for Drug and Health Product Safety have approved the study protocol (2021-A00364-37) in its version 1. Patients will provide written consent for participation. The study will be conducted in accordance with the Declaration of Helsinki.

Participants

Eligible patients are adults (age ≥18 years) undergoing a scheduled surgery with an estimated time of 90 min or more and supposed to be painful (with the usual need for postoperative intravenous (IV) morphine patient-controlled analgesia (PCA)). The surgical specialties concerned are ENT, plastic, digestive, urologic, and gynecologic surgery. Eligible patients must be French-speaking and must have sufficient cognitive ability to complete a questionnaire. The exclusion criteria are surgery with an orthopedic procedure (e.g., osteosynthesis), need for rapid sequence anesthetic induction, pregnancy or lactation, severe psychiatric or cognitive disorder interfering with questionnaire assessment, body mass index < 18 or > 39 kg/m², any contraindication to study drugs, porphyria, uncontrolled epilepsy, unstable cardiac insufficiency, chronic renal or hepatic failure, preoperative bradycardia with an atrioventricular block (2nd or 3rd degree), chronic beta-blocker treatment, and ongoing treatment with a QT interval prolonging drug.

Information of patients

During the anesthesia consultation, investigators will verify inclusion/exclusion criteria. The investigator will invite the patients to participate. Patients will receive complete information in faithful terms and understandable language concerning the objectives, the required follow-up, the risks, the safety measures, and the right to refuse to participate or stop the study at any time. The investigator obtained written informed consent signed by both the investigator and the patient.

Randomization and blinding

The included patients will be randomized to one of the two groups (OFA or standard of care) using a web-based

---

**Trial registration:** ClinicalTrials.gov NCT04797312. Registered on 15 March 2021

**Keywords:** Anesthesia, Opioid-free anesthesia, Opioid-related adverse effects, Quality of recovery, Quality of life, Perioperative care, Patient-reported outcome measures
| **Opioid free anesthesia protocol** | **Standard anesthesia protocol** |
|-----------------------------------|---------------------------------|
| **Before surgery**                | **Locoregional anesthesia if needed, with or without opioids** |
| - CLONIDINE continuous infusion: start at 50 µg/h, with anesthetic monitoring, and adapt to hemodynamic stability with a maximum infusion rate of 150 µg/h. If patient’s weight <50kg, maximum infusion rate of 100µg/h | - Antibiotic prophylaxis if indicated |
| - Locoregional anesthesia if needed, but without opioids | - Hypnotic drugs: left at the discretion of the anesthesiologist |
| **Anesthesia induction**           | **Opioids:** |
| - Antibiotic prophylaxis if indicated | o Sufentanil 0.1-0.3 µg/kg IV |
| - Hypnotic drugs: left at the discretion of the anesthesiologist | Or |
| - NO OPIOIDS                       | o Remifentanil via target-controlled Infusion, |
| - CLONIDINE continuous infusion on same infusion rate, adapt to hemodynamic stability | target: 3-6 ng/mL |
| - MAGNESIUM sulfate: 40 mg/kg, diluted in 100ml of NaCl 0.9%, IV infusion | **KETAMINE:** left at the discretion of the anesthesiologist in charge, 0.15 mg/kg IV, can be repeated every 45 min-1hour |
| Maximum dose: 4 g                  | - Neuromuscular blocking agents (anesthesiologist’s discretion) |
| - LIDOCAINE: 1.5 mg/kg in 10 minutes (continuous infusion) (if loco-regional anesthesia, this dose is not administered) | - Nausea and vomiting management |
| - KETAMINE: 0.5 mg/kg as a bolus or 0.25 mg/kg if instable coronary disease or instable cardiac failure or pulmonary arterial hypertension | **Intra-operative anesthesia** |
| - Neuromuscular blocking agents (anesthesiologist’s discretion) | - Hypnotic drugs: left at the discretion of the anesthesiologist |
| - Nausea and vomiting management | o Inhalation anesthetic agents: Desflurane or Sevoflurane with a MAC (Mean Alveolar Concentration) objective of 1-1.5 MAC |
| | OR |
| | o Propofol via target-controlled infusion, target at 3-6 µg/mL |
| **No Opioids**                     | **Opioids:** |
| - CLONIDINE on continuous infusion on same infusion rate, adapt to hemodynamic stability | o Sufentanil 0.1-0.3 µg/kg with bolus intervals left at the discretion of the anesthesiologist in charge |
| - KETAMINE: 0.2 mg/kg/h on continuous infusion, stopped 30 minutes before end of surgery | OR |
| - LIDOCAINE on continuous infusion: 1.5 mg/kg/h, continued up to 1h after the surgery | o Remifentanil via target-controlled Infusion, target: 3-6ng/mL |
| - Pain management according to the service protocol: | **Pain management according to the service protocol:** |
| o ACETAMINOPHEN 1 g IV | o ACETAMINOPHEN 1 g IV |
| o +/- NEFOPAM 20 mg IV | o +/- NEFOPAM 20 mg IV |
| o +/- KETOPROFEN 50 to 100 mg IV | o +/- KETOPROFEN 50 to 100 mg IV |
| o No opioids | o +/- OXYCODONE or MORPHINE 1-5 mg IV |
| - Neuromuscular blocking agents left at the discretion of anesthesiologist | - Neuromuscular blocking agents left at the discretion of anesthesiologist |
| **Postanesthesia care unit (PACU)** | **Pain management** (opioids can be used if necessary) |
| - LIDOCAINE on continuous Infusion: 1.5 mg/kg/h, continued up to 1 hour after the surgery in the PACU | - Nausea and vomiting management |
| - Pain management (opioids can be used if necessary) | **Nausea and vomiting management** |
| - Nausea and vomiting management |  

Fig. 1 Detailed interventional protocols in the opioid-free anesthesia group (OFA group) and in the standard anesthesia group (English translation from our French procedures). IV, intravenous; PACU, postanesthesia care unit.
Patients will be randomized in one of the two groups with a 1:1 ratio, using a minimization algorithm defined by the randomization methodologist (with a probabilistic component), based on two factors: the type of surgery (ENT, plastic, digestive, urologic and gynecologic surgery) and the surgery severity (assessed by the Surgical Outcome Risk Tool (SORT) score, which can be classified in minor, intermediate, major and major/complex surgery, and which is available online at www.sortsurgery.com). Investigators do not know this equation and will not be able to guess the next randomization arm.

The anesthesia team performing the general anesthesia will be unblinded on the allocation group. The patient will be kept blinded to the protocol allocation, as the nurses and the medical team involved in the postoperative care and outcomes evaluation. For outcomes requiring a phone call, evaluators will be blinded to the allocation group.

### Intervention
The study aims to compare an OFA protocol to an anesthesia protocol based on standard practices. In both arms, patients will undergo general anesthesia, combined or not with local or regional anesthesia. The two protocols are detailed in Fig. 1.

None of the patients will receive premedication. Anesthetic monitoring will be the same in both groups, including pulse oximetry, electrocardiography, non-invasive blood pressure and/or invasive monitoring when indicated, body temperature, muscle relaxation (train-of-four stimulation), and bispectral index.

The OFA protocol (OFA group) begins before surgery with a clonidine infusion (under cardiac monitoring) at an initial rate of $50\,\mu g/h$, and then adapted according to hemodynamic stability (to keep systolic blood pressure in a range of $\pm 20\%$ its basal value) with a maximal rate of $150\,\mu g/h$ ($100\,\mu g/h$ for patients with body weight $<50$ kg). Anesthesia will be induced and maintained with hypnotic drugs and curare left at the anesthesiologist’s discretion. No opioids should be infused. The clonidine infusion should be continued at the same infusion rate. The OFA protocol includes a magnesium sulfate infusion ($40\,mg/kg$), a lidocaine infusion ($1.5\,mg/kg$ bolus dose in 10 min followed by $1.5\,mg/kg/h$ continuous infusion), and a ketamine infusion ($0.5\,mg/kg$ bolus dose followed by a $0.2\,mg/kg/h$ continuous infusion).

### Table: ALLOCATION and POST ALLOCATION

| Timepoints         | Allocation | Baseline | During surgery | PACU | H24 | H48 | H72 | D7 | Discharge or D30 | M3 |
|-------------------|------------|----------|----------------|------|-----|-----|-----|----|-----------------|----|
| Eligibility screening | X          |          |                |      |     |     |     |    |                 |    |
| Informed consent  | X          |          |                |      |     |     |     |    |                 |    |
| INTERVENTIONS     |            |          |                |      |     |     |     |    |                 |    |
| OFA group         |            | [_____]  |                |      |     |     |     |    |                 |    |
| Control group     | [_____]    |          |                |      |     |     |     |    |                 |    |
| ASSESSMENTS       |            | X        |                |      |     |     |     |    |                 |    |
| Inclusion/exclusion criteria | X          |          |                |      |     |     |     |    |                 |    |
| Demographic characteristics, comorbidities | X          |          |                |      |     |     |     |    |                 |    |
| Surgical and anesthesia characteristics | X          |          |                |      |     |     |     |    |                 |    |
| Compliance with protocol | X          |          |                |      |     |     |     |    |                 |    |
| Intra-operative complications | X          |          |                |      |     |     |     |    |                 |    |
| Surgeon and anesthesiologist satisfaction | X          |          |                |      |     |     |     |    |                 |    |
| Adverse event related to the protocol | X          | X        | X              | X    | X   | X   |     |    |                 |    |
| Opioid analgesic rescue doses | X          | X        | X              | X    | X   | X   |     |    |                 |    |
| Opioid side effects | X          | X        |                |      |     |     |     |    |                 |    |
| Pain intensity    | X          | X        | X              | X    |     |     |     |    |                 |    |
| Length of stays   | X          |          |                |      |     |     |     |    |                 |    |
| Quality of recovery (QoR-15) | X          | X        | X              |      |     |     |     |    |                 |    |
| Bowel movement, postoperative complications | X          | X        |                |      |     |     |     |    |                 |    |
| Patient satisfaction and memorization | X          |          |                |      |     |     |     |    |                 |    |
| Surgical revision | X          |          |                |      |     |     |     |    |                 |    |
| Chronic pain (BPI), neuropathic pain (DN-4) | X          | X        |                |      |     |     |     |    |                 |    |
| Quality of Life (EQ-5D-3L) | X          |          |                |      |     |     |     |    |                 |    |

Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (adapted from SPIRIT figure). BPI, Brief Pain Inventory; D7, 7 days after surgery; D30, 30 days after surgery; H24, 24 hours after surgery; H48, 48 hours after surgery; H72, 72 hours after surgery; M3, 3 months after surgery; OFA, opioid-free anesthesia; PACU, postanesthesia care unit.
ketamine infusion should be stopped 30 min before the end of the surgery, and the lidocaine infusion will be stopped after 1 h in the postanesthesia care unit (PACU).

The standard anesthesia protocol associates hypnotic drugs, curare, and opioids (sufentanil or remifentanil) left at the discretion of the anesthetist in charge. A low-dose ketamine bolus (0.15 mg/kg) is allowed at anesthesia induction, possibly followed by repeated boluses since it is commonly used in our standard practice.

In both arms, according to recent recommendations, anesthesiologists are prompted to infuse an antimicrobial prophylaxis [17], to apply a protective ventilation strategy (tidal volume between 6 and 8 ml/kg, respiratory rate for an end-tidal CO₂ value at 35–40 mmHg, a positive end expiratory pressure) [18], and to treat perioperative hypotension and hypovolemia [19]. The depth of anesthesia is monitored by a bispectral index sensor (target 40–60). Postoperative pain, nausea, and vomiting are managed according to the unit protocols. The use of local or regional anesthesia is allowed in both groups (in the OFA group, the protocol stipulates not to use opioids as adjuvant). In the PACU, if the patient experiences acute pain (defined as a pain analog scale ≥ 4), morphine or oxycodone titration will be started (bolus of 1 to 2 mg, with a 5-min delay between two doses) until pain relief is achieved. The analgesic management will be continued in the ward using IV PCA and/or oral opioids. The doses of opioids (i.e., morphine and oxycodone) will be converted into morphine-equivalent doses according to the following rule: 1 mg oral morphine = 1/2 mg oral oxycodone = 1/3 mg IV morphine; 1 mg IV morphine = 1 mg IV oxycodone. Patients will be discharged to the ward when their modified Aldrete score is ≥ 12 [20].

Outcomes

Primary outcome

The primary outcome is the early postoperative quality of recovery, assessed via the French version of the QoR-
rate of neuropathic pain diagnosed using the DN-4 questionnaire [29].

Sample size
According to the database used to assess the French version of the QoR-15 that included 72 patients undergoing gynecologic, digestive, or urologic major surgery, the mean QoR-15 score was 97 at 24 h after the surgery, with a standard deviation of 16. A difference of at least 8.0 points in the score is considered clinically significant [30]. The OFA will thus be superior to the standard of care if the mean QoR-15 is at least 105. Considering a type I error risk of 0.05 in two-sided test and a power of 0.8, the estimated number of patients needed is 126 (63 patients in both groups). Considering that data will not be available for ten percent of the patients (e.g., surgery canceled, lost in follow-up, consent withdrawal) regarding the primary outcome, we plan to include 140 patients.

Follow-up
Nine visits are scheduled for all patients enrolled in the study. The plan summarizing the follow-up visits is presented in Fig. 2. The time T0 (hour 0/day 0) is the time of the surgical incision. The following data will be recorded at inclusion: demographic data, weight and height, ASA physical status classification, surgery type, and comorbidities. The SORT classification will also be recorded.

Perioperative surgical and anesthetic data will be recorded, including total dose of each medication. The anesthesiologist and the surgeon will also grade their satisfaction concerning the anesthesia.

In PACU, the total dose of pain medications, the occurrence of any complication, including postoperative nausea and vomiting (PONV), numerical pain rating scale, and PACU length of stay (in hours) will be recorded. In the ward visits (at 24, 48, and 72 h after the surgery), we will record the following data: QoR-15 questionnaire, maximal numerical effort pain scale, the occurrence of complications (using the POMS classification), morphine consumption, bowel movement, adverse event, and patient satisfaction (only at 24 h after the surgery). The QoR-15 questionnaires will be completed by the patient himself whenever possible, who could be helped by a nurse blinded to the assignment group, or by phone if the patient has returned home.

At 7 days, we will collect the morphine or equivalent daily consumption and the occurrence of surgical revision. The following data will be recorded at the hospital discharged visit (or 30 days after surgery): total length of stay and occurrence of in-hospital opioid side effects. A phone call to the patient will be made at 3-month to record the BPI, the DN-4, and the EQ-5D scores.
Safety
Safety items will be collected during follow-up by the anesthesia team (during surgery) and participating investigators during other visits. Various events will be collected during the anesthesia and surgery (e.g., episodes of arterial hypertension or hypotension, episodes of bradycardia, a suspected hypersensitivity reaction, and surgical complications). The occurrence of other adverse events that may be attributable to the protocol will be collected during the other follow-up visits (at 24 h, 48 h, 72 h, 7 days, and until discharge (censored at 30 days)). The occurrence of a serious adverse event will be collected at any time during the patient’s follow-up (up to 3 months), whose imputability with one of the allocation groups will be discussed. Details of safety monitoring are available in the supplementary material.

Data collection and study monitoring
Data will be entered into the electronic web-based case report form (eCRF on Ennov Clinical®). We will establish the database from the eCRFs.

A clinical research associate (CRA) mandated by the study sponsor will ensure the successful completion of the study, the collection of data, documentation, recording, and report, in accordance with the Standard Operating Procedures implemented in the Angers Hospital and in accordance with Good Clinical Practice, laws, and regulations.

The following items will be reviewed for every fifteen included patients:

- Signed informed consent,
- Compliance with the study protocol and procedures that are defined,
- Quality of data collected in the case report form: accuracy, missing data, data consistency with the documents “source” (medical records, appointment books, original lab results, etc.).

After monitoring data on site, an automated check of the data entered will be made by the data management team based on the data validation plan signed by the coordinating investigator. Detected errors will lead to the issuance of requests for information and electronic correction.

Statistical analysis
All analyses will be performed with R software (version 3.6.3). The main analysis will be in intention-to-treat and will include all randomized patients. Patients will be analyzed according to their randomization group. A per-protocol analysis will be performed as a sensitivity analysis to assess the main analysis robustness. A flow chart of all patients (Fig. 3) and descriptive statistics will be used to describe baseline characteristics. Data will be presented by their mean with standard deviation, median with interquartile range, number with the percentage of sample (%), or 95% confidence interval, according to their normal or non-normal distribution. We will report both absolute and relative measures for the comparisons between endpoints.

For the primary endpoint, we will use multivariate imputation for chained equations (with five imputations) via the mice package in R and perform a pooled-linear regression model, allowing us to perform an intention-to-treat analysis even if missing data. The covariates included in this analysis will be the allocation group, the type, and the surgery severity. This statistical method will also be used to analyze the QoR-15 at 48 and 72 h as secondary endpoints. To eliminate any influence of the phone evaluation, we will perform a sensitivity analysis just on the QoR-15 surveys collected in the ward.

We will also impute data for the analyses of other secondary endpoints: the rate of chronic pain patients at three months identified by the BPI via a logistic regression (same adjustment covariates) as well as for EQ-5D visual analog score via a linear regression (same adjustment covariates). The other endpoints will not be analyzed with the multiple imputation method. We reserve imputation for the endpoints included in the hierarchical scheme of the type I error management.

For each of the analyses involving the multiple imputation method, sensitivity analyses will be performed if the missing data rate for the endpoint of interest is greater than 10%. We will conduct an analysis only on the complete cases, as well as best-worst and worst-best case sensitivity analyses. For the best worst-case scenario, it is assumed that all participants lost to follow-up will have a beneficial outcome; and all those with missing outcomes in the other scenario will have a harmful outcome. For continuous outcomes, the beneficial outcome will be the group mean plus one standard deviation of the group mean, and the harmful outcome will be the group mean minus one standard deviation of the group mean [31]. To eliminate the potential risk of a violation of the normality, we will confirm the results for continuous variable implicating in the hierarchical scheme by sensitivity analysis using a semi-parametric approach with an ordinal model [32].

Concerning the pain evolution and morphine consumption variation, we will analyze those outcomes using a mixed effects linear regression model (fixed effect for the treatment arm, a fixed effect for the time frame, a fixed effect for each minimization factor, and a random effect for the patients). Hospital and PACU length of stays, as well as satisfactions (those of the surgeon, those of the anesthesiologist, those of the patient), will be compared using a linear regression model.
The proportion of complications of the POMS will be defined as a categorical variable (four levels: no complication, one complication, two complications, and more than 3 complications) and will be analyzed using a logistic regression model (allocation group and the minimization factors as covariates). Pain characteristics described by BPI and the proportion of patients in each of the five scales of EQ-5D will not be compared but only described.

All statistical analyses will be performed by two-sided tests. The signification cutoff will be a $p$ value < 0.05 with 95% confidence interval.

**Type I error management**

We will manage the type I error in a sequential hierarchical manner (Fig. 4). We will test the first endpoint (i.e., QoR-15 at H24), and if the $p$ value is less than 0.05, we will conclude that there is evidence of an effect. Then, we will test the following endpoint (i.e., QoR-15 at H48) using a significance level of 0.05. We will continue to test each endpoint of the hierarchical classification either up to the last endpoint (i.e., the quality of life by the EQ-5D visual analog scale at 3 months) or if we observe a non-significant result. Suppose a non-significant result ($p$ value > 0.05) for one of the endpoints is observed. In that case, we will perform the following statistical comparisons in an exploratory manner without drawing any clinical conclusion.

No interim analysis is planned during the inclusion period.

**Discussion**

Although OFA seems promising in the context of the opioid crisis, data are needed to objective its interest; our study will be powered to evaluate the impact of OFA on early QoR and give useful information on long-term benefit of reducing perioperative opioid use. In addition, we choose to use a combination of lidocaine, magnesium sulfate, ketamine, and clonidine to perform OFA. Other studies are underway which attempt to evaluate the quality of postoperative recovery using OFA, but either do not fully assess this “full” combination of drugs [33], or do not propose a continuous infusion throughout surgery [34]. In addition, we plan to evaluate OFA in a wide range of surgeries, while other studies focus on one type of surgical procedure only, in order to provide more generalizable results.

We choose to combine these different pharmacological classes during surgery for their different effects: analgesia, anti-hyperalgesia, anti-inflammatory effect, anti-nausea and anti-vomiting, and reduction of the neurohumoral stress response. In the anesthesia literature, different OFA protocols were described [35]. While OFA using dexmedetomidine has been reported to be effective during several types of surgery [13, 36], it may promote side effects, including increased risk of bradycardia and hypoxemia [9]. We thus prefer to incorporate clonidine as an alpha-2 agonist agent in our OFA protocol, because this molecule seems to be less responsible for severe bradycardia episodes [37] and seems to have longer positive effects [38].

To evaluate OFA, we choose primary criteria focused on patients’ overall recovery. Indeed, in a recent international consensus, the SteP–COMPAC group has highlighted the value of postoperative recovery scales for standardizing outcomes in perioperative medicine [25]. The QoR-15 questionnaire appears reliable, sensitive, and easily achievable in clinical practice (2 to 3 min for the questionnaire to be fully completed). It gives information on postoperative recovery in a unidimensional approach, and the patient can complete the questionnaire alone or with the help of an assessor. Therefore, different studies have used this questionnaire to evaluate the impact of an intervention on patients’ perception of postoperative recovery [26]. Beyond assessing the quality of early recovery, we will also study the longer-term

| OFA group versus Standard anesthesia group |
|-------------------------------------------|
| QoR-15 score at 24 hours after surgery    |
| QoR-15 score at 48 hours after surgery    |
| QoR-15 score at 72 hours after surgery    |
| Proportion of chronic pain patients at 3 months |
| Quality of life (VAS EQ-5D) at 3 months  |

If $p$ < 0.05, we reject the null hypothesis (H0), and we continue the statistical comparisons according to the hierarchical order.

---

**Fig. 4** Diagram of the hierarchical classification of the statistical tests (type I error management). OFA, opioid-free anesthesia; VAS, visual analog scale.
status (i.e., at 3 months). The study aims to investigate the pain profile of the patients, detect the presence of chronic pain, neuropathic pain, and estimate their quality of life. To our knowledge, our study would be the first to evaluate OFA on these long-term criteria.

In a nutshell, this study will compare an OFA protocol (based on a combination of four agents: clonidine, ketamine, magnesium sulfate, and lidocaine) versus a standard anesthesia protocol in patients scheduled for major non-orthopedic surgery, on their early QoR but also on their pain status and their quality of life at 3 months. The findings will also provide evidence of potential adverse events associated with this OFA protocol, helping to assess the benefit/risk ratio of the use of such a pharmacological combination.

**Trial status**

This study was approved by the French Institutional Review Board “Eastern III” (Nancy, France, number: 2021-A00364-37) and the National Agency for Drug and Health Product Safety, and registered at ClinicalTrials.gov (NCT04797312) on 15 March 2021. The recruitment of participants started in July 2021. The anticipated period is 18 months.

**Abbreviations**

BPI: Brief Pain Inventory; ENT: Ear, nose, and throat; EQ-SD: Euroqol-SD score; IV: Intravenous; OFA: Opioid-free anesthesia; PACU: Post anesthesia care unit; PCA: Patient-controlled analgesia; POMS: Postoperative morbidity survey; POIV: Postoperative nausea and vomiting; QoR: Quality of recovery; SORT: Surgical Outcome Risk Tool

**Acknowledgements**

Not applicable

**Authors’ contributions**

ML conceived the study and led the proposal and protocol development. SPR, TP, and FC contributed to the study design and the development of the proposal. EPS was the lead trial methodologist. ER, SL read the manuscript critically and provided relevant comments. All authors reviewed, read, and approved the final manuscript. All named authors adhere to the authorship guidelines of Trials; the authors have agreed to the publication and have contributed to the writing of the manuscript.

**Funding**

This study will solely be supported by the Angers University Hospital. The sponsor played no part in the study design, management, analysis, interpretation of the data, writing of the report, or the decision to submit the report.

**Availability of data and materials**

The data generated could be shared after a request to the corresponding author. Three years after the end of follow-up of the last included patient, we will deliver a completely deidentified dataset to an appropriate data archive for sharing purposes.

**Declarations**

**Consent for publication**

Not applicable

**Competing interests**

All the authors declare that they have no competing interests.

**Author details**

1Département d’Anesthésie Réanimation, Centre Hospitalier Universitaire d’Angers, Angers, France. 2INSERM UMR 1246 - SPHERE, Nantes University, Tours University, Nantes, France. 3Centre Hospitalier Universitaire d’Angers, Département de Biostatistiques et Méthodologie, Angers, France.

**Received:** 6 July 2021 **Accepted:** 13 November 2021

**funding**

This study will solely be supported by the Angers University Hospital. The sponsor played no part in the study design, management, analysis, interpretation of the data, writing of the report, or the decision to submit the report.

**Availability of data and materials**

The data generated could be shared after a request to the corresponding author. Three years after the end of follow-up of the last included patient, we will deliver a completely deidentified dataset to an appropriate data archive for sharing purposes.

**Declarations**

**Consent for publication**

Not applicable

**Competing interests**

All the authors declare that they have no competing interests.

**Author details**

1. Egan TD. Are opioids indispensable for general anaesthesia? Br J Anaesth. 2019;123(6):e127–35. https://doi.org/10.1093/bja/ajz029.2019.02.018.

2. Callinan CE, Neuman MD, Lacy KE, Galbison C, Ashburn MA. The initiation of chronic opioids: a survey of chronic pain patients. J Pain. 2017;18(4):360–5. https://doi.org/10.1016/j.jpain.2016.11.001.

3. Vadivelu N, Kai AM, Kodumudi V, Srmcik J, Kaye AD. The opioid crisis: a comprehensive overview. Curr Pain Headache Rep. 2018;22(3):16. https://doi.org/10.1007/s11916-018-0670-z.

4. American Society of Anesthesiologists Newsletter. Reduce patient exposure to opioids in the surgical setting [Internet]. 2018 [cited 2021 Jun 30]. Available from: https://www.asahq.org/-/media/sites/asahq/files/public/advocacy/federal%20activities/C2018-opioid-one-pager.pdf?la=en.

5. Kumar K, Kirksey MA, Duong S, Wu CL. A review of opioid-sparing modalities in perioperative pain management: methods to decrease opioid use postoperatively. Anesth Analg. 2017;125(5):1749–60. https://doi.org/10.1213/ANE.0000000000002497.

6. Thota RS, Ramkiran S, Garg R, Goswami J, Bavi V, Thomas M. Opioid free onco-anesthesia: is it time to convict opioids? A systematic review of literature. J Anaesthesiol Clin Pharmacol. 2019;35(4):441–52. https://doi.org/10.4103/jacp.JACP_128_19.

7. Bohringer C, Astorga C, Liu H. The benefits of opioid free anesthesia and the precautions necessary when employing it. Transl Perioper Pain Med. 2020;7(1):152–7.

8. Shanithanna H, Ladha KS, Kehlet H, Joshi GP. Perioperative opioid administration. Anesthesiology. 2021;134(4):645–59. https://doi.org/10.1097/ALN.0000000000003572.

9. Boleiell H, Garot M, Lebuffe G, Gerbardt A, Bila J, Vuillon P, et al. Balanced opioid-free anesthesia with dexmedetomidine versus balanced anesthesia with remifentanil for major or intermediate noncardiac surgery. Anesthesiology. 2021;134(4):541–51. https://doi.org/10.1097/ALN.0000000000003725.

10. Hwang W, Lee J, Park J, Joo J. Dexmedetomidine versus remifentanil in postoperative pain control after spinal surgery: a randomized controlled study. BMC Anesthesiol. 2015;15(1):21. https://doi.org/10.1186/s12871-015-0004-1.

11. Hontoir S, Saxena S, Gatto P, Khaliife M, Ben Aziz AM, Paesmans M, et al. Opioid-free anesthesia: what about patient comfort? A prospective, randomized, controlled trial. Acta Anaesthesiol Belg. 2016;67(4):183–90.

12. Toleska M, Dimitrovsky A. Is opioid-free general anesthesia more superior for postoperative pain versus opioid general anesthesia in laparoscopic cholecystectomy? Pril (Makedon Akad Nauk Umjet Odd Med Nauk). 2019;40:81–87.

13. Ziemann-Gimmel P, Goldfarb AA, Koppman J, Mareena RT. Opioid-free total intravenous anaesthesia reduces postoperative nausea and vomiting in bariatric surgery beyond triple prophylaxis. Br J Anaesth. 2014;112(5):906–11. https://doi.org/10.1093/bja/aet551.

14. Frauenknecht J, Kirkham KR, Jacobi-Guillarmod A, Albrecht E. Analgesic impact of intra-operative opioids vs. opioid-free anaesthesia: a systematic review and meta-analysis. Anaesthesia. 2019;74(5):651–62. https://doi.org/10.1111/anae.14582.

15. Salomé A, Harkouk H, Fletcher D, Martinez V. Opioid-free anesthesia benefit-risk balance: a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2021;10(10). https://doi.org/10.3390/jcm10102060.

16. Boleiell H, Sulpic L. Peri-operative pain and its consequences. J Visc Surg. 2016;153(6):S15–7. https://doi.org/10.1016/j.jviscsurg.2016.09.004.

17. Martin C, Auboyer C, Boisson M, Dupont H, Gauthier R, Kitzis M, et al. Antibiotic prophylaxis in surgery and interventional medicine (adult patients).
